Unlike the US, Mexico is bolstering its mRNA offerings with the help of Moderna’s portfolio. The Mexican Government has ...

The FDA’s refusal to review Moderna's flu vaccine, mRNA-1010, comes within a wider push from the US government to alter ...

Gilead’s HIV drugs generated $20.8bn in full-year 2025 sales, up 6% from 2024. This was mainly fuelled by the company’s ...

Insilico Medicine has announced several AI drug discovery collaborations with CMS across several projects in CNS and ...

THX Pharma and Biocodex have entered into a strategic licensing agreement to further the development of two drug candidates, Batten-1 and TX01, targeted at the Batten, Gaucher, and Niemann-Pick type C ...

Early-phase oncology trials carry substantial scientific and commercial risk in cancer drug development. Getting them right ...

RWD and RWE are reshaping the design of clinical trials, making them smarter, faster, and more efficient. Read more here: ...

Novo and Hims & Hers have continually locked horns over the legality of obesity drug offerings. Hims & Hers has abandoned ...

Takeda has entered into a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule ...

REGENXBIO has received a CRL from the US FDA related to its BLA for RGX-121 to treat MPS II, also called hunter syndrome.

Under the deal, AbbVie agreed to lower prices on certain Medicaid drugs and expand distribution via the TrumpRx direct-to-patient platform.

AstraZeneca’s cancer medicine sales rose 14% in 2025, with upcoming disease expansions a foundation for further growth in 2026.